专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010041722A2 PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：药物组合物
公开(公告)号：WO2010041722A2
公开(公告)日：2010-04-15
申请号：PCT/JP2009067586
申请日：2009-10-02
申请人： R TECH UENO LTD , SUCAMPO AG , HARADA YASUHIRO , KAWASAKI JUNICHI , HAYASHI TADASHI , UENO RYUJI
发明人： HARADA YASUHIRO , KAWASAKI JUNICHI , HAYASHI TADASHI , UENO RYUJI
IPC分类号： A61K9/00 , A61K47/10 , A61K47/26
CPC分类号： A61K9/0048 , A61K31/557 , A61K47/10 , A61K47/26
摘要： Provided is a pharmaceutical composition comprising: a) a prostaglandin compound; (b) a sugar alcohol; (c) a polyol; and (d) a pharmaceutically acceptable carrier. The composition of the present invention can be stored stably even in a polyethylene container. In addition, the composition of the present invention can be stored stably for a long term even if it comprises only a small amount of a preserving agent.
摘要翻译：本发明提供药物组合物，其包含：a）前列腺素化合物; （b）糖醇; （c）多元醇; 和（d）药学上可接受的载体。本发明的组合物可以稳定地储存在聚乙烯容器中。此外，即使只含有少量的防腐剂，本发明的组合物可以长期稳定地储存。

2. 发明申请

WO2012141334A1 AQUEOUS OPHTHALMIC COMPOSITION 审中-公开
标题翻译：水性眼科组合物（AQUEOUS OPHTHALMIC COMPOSITION）
公开(公告)号：WO2012141334A1
公开(公告)日：2012-10-18
申请号：PCT/JP2012/060394
申请日：2012-04-11
申请人： R-TECH UENO, LTD. , MASHIMA, Yukihiko , HARADA, Yasuhiro , KAWASAKI, Junichi , UENO, Ryuji
发明人： MASHIMA, Yukihiko , HARADA, Yasuhiro , KAWASAKI, Junichi , UENO, Ryuji
IPC分类号： A61K31/5575 , A61K9/08 , A61K47/04 , A61K47/18 , A61K47/34 , A61P27/02
CPC分类号： A61K33/22 , A61K9/0048 , A61K31/5575 , A61K47/14
摘要： Disclosed is an aqueous ophthalmic composition comprising (a) a fatty acid derivative such as a prostaglandin derivative, (b) a polyoxyethylene sorbitan fatty acid ester, (c) an edetic acid compound, (d) a boric acid and a salt of a boric acid, (e) a pharmaceutically acceptable aqueous carrier, and (f) no more than 0.005w/v% of benzalkonium chloride. The composition is stable and has good anti-microbial properties.
摘要翻译：本发明提供一种水性眼用组合物，其包含（a）前列腺素衍生物等脂肪酸衍生物，（b）聚氧乙烯失水山梨糖醇脂肪酸酯，（c）乙二胺化合物，（d）硼酸和硼酸盐酸，（e）药学上可接受的水性载体，和（f）不超过0.005w / v％的苯扎氯铵。组合物稳定，抗微生物性能好。

3. 发明申请

WO2010041722A3 PHARMACEUTICAL COMPOSITION COMPRISING A PROSTAGLANDIN 审中-公开
公开(公告)号：WO2010041722A3
公开(公告)日：2010-04-15
申请号：PCT/JP2009/067586
申请日：2009-10-02
申请人： R-TECH UENO, LTD. , SUCAMPO AG , HARADA, Yasuhiro , KAWASAKI, Junichi , HAYASHI, Tadashi , UENO, Ryuji
发明人： HARADA, Yasuhiro , KAWASAKI, Junichi , HAYASHI, Tadashi , UENO, Ryuji
IPC分类号： A61K9/00 , A61K47/10 , A61K47/26
摘要： Provided is a pharmaceutical composition comprising: a) a prostaglandin compound; (b) a sugar alcohol; (c) a polyol; and (d) a pharmaceutically acceptable carrier. The composition of the present invention can be stored stably even in a polyethylene container. In addition, the composition of the present invention can be stored stably for a long term even if it comprises only a small amount of a preserving agent.

4. 发明申请

WO2009011449A3 PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY-PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND 审中-公开
公开(公告)号：WO2009011449A3
公开(公告)日：2009-01-22
申请号：PCT/JP2008/063222
申请日：2008-07-16
申请人： R-TECH UENO, LTD. , SUCAMPO AG , HARADA, Yasuhiro , KAWASAKI, Junichi , NISHIMURA, Yoshie , UENO, Ryuji
发明人： HARADA, Yasuhiro , KAWASAKI, Junichi , NISHIMURA, Yoshie , UENO, Ryuji
IPC分类号： A61K9/48 , A61K31/5575
摘要： Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.

5. 发明申请

WO2009011449A2 PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY-PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND 审中-公开
标题翻译：包含11-DEOXY-PROSTAGLANDIN化合物的药物组合物和用于稳定化合物的方法
公开(公告)号：WO2009011449A2
公开(公告)日：2009-01-22
申请号：PCT/JP2008063222
申请日：2008-07-16
申请人： R TECH UENO LTD , SUCAMPO AG , HARADA YASUHIRO , KAWASAKI JUNICHI , NISHIMURA YOSHIE , UENO RYUJI
发明人： HARADA YASUHIRO , KAWASAKI JUNICHI , NISHIMURA YOSHIE , UENO RYUJI
IPC分类号： A61K9/48 , A61K31/5575
CPC分类号： A61K47/14 , A61K9/4858 , A61K31/5575
摘要： Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized
摘要翻译：本发明提供包含式（I）表示的11-脱氧前列腺素化合物和脂肪酸酯的药物组合物。通过混合式（I）化合物和脂肪酸酯，式（I）化合物将稳定

6. 发明申请

WO2003026659A1 LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF 审中-公开
标题翻译：低剂量阿维替唑药物及其制备方法
公开(公告)号：WO2003026659A1
公开(公告)日：2003-04-03
申请号：PCT/JP2002/009858
申请日：2002-09-25
申请人： OTSUKA PHARMACEUTICAL CO., LTD. , BANDO, Takuji , AOKI, Satoshi , KAWASAKI, Junichi , ISHIGAMI, Makoto , TANIGUCHI, Youichi , YABUUCHI, Tsuyoshi , FUJIMOTO, Kiyoshi , NISHIOKA, Yoshihiro , KOBAYASHI, Noriyuki , FUJIMURA, Tsutomu , TAKAHASHI, Masanori , ABE, Kaoru , NAKAGAWA, Tomonori , SHINHAMA, Koichi , UTSUMI, Naoto , TOMINAGA, Michiaki , OI, Yoshihiro , YAMADA, Shohei , TOMIKAWA, Kenji
发明人： BANDO, Takuji , AOKI, Satoshi , KAWASAKI, Junichi , ISHIGAMI, Makoto , TANIGUCHI, Youichi , YABUUCHI, Tsuyoshi , FUJIMOTO, Kiyoshi , NISHIOKA, Yoshihiro , KOBAYASHI, Noriyuki , FUJIMURA, Tsutomu , TAKAHASHI, Masanori , ABE, Kaoru , NAKAGAWA, Tomonori , SHINHAMA, Koichi , UTSUMI, Naoto , TOMINAGA, Michiaki , OI, Yoshihiro , YAMADA, Shohei , TOMIKAWA, Kenji
IPC分类号： A61K31/496
CPC分类号： C07D215/227 , C07B2200/13 , C07D215/22 , Y10T428/2982
摘要： The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.
摘要翻译：本发明提供低吸湿形式的阿立哌唑及其制备方法，即使当含有阿立哌唑酐晶体的药物制剂长时间储存时，其也不会转化为水合物或丧失其原始溶解度。

7. 发明申请

WO2007013477A1 PHARMACEUTICAL COMPOSITION COMPRISING 2 , 3-DIHYDRO-6-NITROIMIDAZO [2 , 1-B] OXAZOLE DERIVATIVES 审中-公开
标题翻译：包含2,3-二羟基-6-硝基咪唑并[2,1-B]氧代唑衍生物的药物组合物
公开(公告)号：WO2007013477A1
公开(公告)日：2007-02-01
申请号：PCT/JP2006/314708
申请日：2006-07-19
申请人： OTSUKA PHARMACEUTICAL CO., LTD. , KAWASAKI, Junichi
发明人： KAWASAKI, Junichi
IPC分类号： A61K9/14 , A61K31/454 , A61K31/496 , A61K31/47
CPC分类号： A61K9/1652 , A61K9/1617 , A61K31/454 , A61K31/47 , A61K31/496
摘要： A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R 1 represents a hydrogen atom or C 1-6 alkyl group; n represents an integer from 0 to 6; and R 2 represents, for example, a group of general formula (A) shown below: wherein R 3 represents a phenoxy group, optionally substituted on the phenyl ring with one or more members selected from the group consisting of halogen atoms, halo-substituted or unsubstituted C 1-6 alkyl groups, and halo-substituted or unsubstituted C 1-6 alkoxy groups; and (II) at least one cellulose compound selected from the group consisting of hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate. The present pharmaceutical composition has an improved oxazole compound water solubility.
摘要翻译：根据本发明的药物组合物包含：（I）选自恶唑化合物，其旋光异构体及其盐中的至少一种，恶唑化合物由通式（1）表示：其中R < SUP> 1 表示氢原子或C 1-6烷基; n表示0〜6的整数，和R 2表示例如下列通式（A）的基团：其中R 3表示苯氧基，任选地在苯环上被一个或多个选自卤素原子，卤素取代或未取代的C 1-6烷基和卤素取代或未取代的C 1-6烷氧基的更多成员; 和（II）至少一种选自羟丙基甲基纤维素邻苯二甲酸酯和羟丙基甲基纤维素乙酸酯琥珀酸酯的纤维素化合物。本药物组合物具有改善的恶唑化合物水溶性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式